(Dad) Re: PSK

Do I have to go into a regulated study to get the shark fin? I'll take anything, and all of them at the same time, if its safe. Proven safe. I don't need to know which one was the one that worked. this isn't science, it's me. dad

Liza May wrote:

This is an abstract presented at last year's ASCO conference (this
year's will be held in May). Anyway, I'm looking for whatever I can find
on the results of the many open ongoing trials, and the societies
conference proceedings are a good place to find information that is hard
to come by otherwise. This particular abstract discusses a study
combining PSK (which is shark cartilage) with UFT (which is Xeloda - we
don't want that). Dad, everything on PSK that I have ever read, and
continue to turn up, is good.

Love Liza

Postoperative Adjuvant Immunochemotherapy Using Protein-Bound
Polysaccharide K (PSK) and Tegafur·Uracil (UFT) Improves Disease-Free
Survival: Results of a Randomized Controlled Trial (GOSG-C Study).

Susumu Ohwada, Susumu Kawate, Yoshiyuki Kawashima, Toshiroh Ikeya,
Takashi Nakajima, Yasuo Morishita, Gunma University Faculty of Medicine,
Maebashi, Japan; Maebashi Red Cross Hospital, Gunma, Maebashi, Japan.

It has been reported that 5-FU in combination with PSK, an extract from
cultured mycelia of Basidiomycetes, is more effective than 5-FU alone
for adjuvant therapy setting in gastric cancer (Lancet 343, 1122-1126,
1994) and in colon cancer (Proc ASCO, 1999). PSK restores the suppressed
immune response by tumor burden, and recently has been reported to
improve the impaired anti-tumor CD4+ T-cell response through suppression
of TGF-[Szlig] production (Int. J. Cancer: 70, 362-372, 1997). We have
assessed the efficacy of PSK in combination with UFT by a randomized,
controlled clinical trial on colorectal cancer with Stage II and III.
Between October 1994 and March 1997, 207 patients were assigned to two
groups (Group P: UFT 300mg/day + PSK 3g/day orally, Group C: UFT
300mg/day orally). The respective treatment continued for two years
after surgery. Seven (3%) patients were declared ineligible or dropped
out, and there were no significant biases between two groups. The
combined modality regimen in this program was well tolerated, and
compliance was good. The main statistical endpoints were disease-free
survival (DFS) and overall survival (OS). DFS showed a significant
difference (p=0.021), 80.5% for Group P and 68.7% for Group C three
years after surgery. The 3-year OS was 87.2% for Group P and 80.6% for
Group C (p=0.247). These results demonstrate that PSK + UFT improved DFS
by 11.8% and OS by 6.6% compared with UFT alone. The follow-up period
was not long enough to detect the OS difference. However, we will
monitor the survival rates up to five years after surgery. We conclude
that postoperative adjuvant immunochemotherapy using PSK + UFT is highly
effective in preventing recurrence of colorectal cancer. We also suggest
that this combination is able to prolong the overall survival time.